LIAISON® SARS-CoV-2 TrimericS IgG by DiaSorin Ltd

Manufacturer DiaSorin Ltd
The LIAISON® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.


LIAISON® SARS-CoV-2 TrimericS IgG by DiaSorin Ltd product image
LIAISON® SARS-CoV-2 TrimericS IgG

The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.



0 Scientists have reviewed this product


Write the First Review

No Reviews

A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies

The LIAISON® SARS-CoV-2 TrimericS IgG assay is the second generation of DiaSorin serological tests with an important diagnostics improvement. The selection of a new recombinant Trimeric Spike glycoprotein as a capture antigen, offers a new product with high standard quality that provides the following benefits:

  • A quantitative assay for the detection of IgG antibodies anti-Trimeric Spike glycoprotein of SARS-CoV-2
  • Trimeric Spike Glycoprotein is the stabilized native form of the SARS-CoV-2 Spike protein and a stabilized trimer may elicit an accurate detection of IgG Neutralizing antibodies
  • Clinical Sensitivity: 98.7% - Clinical Specificity: 99.5%
  • Correlation with Microneutralization test: PPA: 100%, NPA: 96.9%
  • A fully automated solution with up to 171 results/hour on LIAISON® XL
  • Complete traceability combined with a simplified sample workflow

Product Overview

LIAISON® SARS-CoV-2 TrimericS IgG by DiaSorin Ltd product image

LIAISON® SARS-CoV-2 TrimericS IgG

Manufacturer DiaSorin Ltd

Be the first to review this product